Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CLK1 | P49759 | 5/20 | 0.35 |
| ▸ | CLK2 | P49760 | 4/20 | 0.35 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.35 |
| ▸ | DYRK1B | Q9Y463 | 4/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2907471 | 1.00 | NPC1 (0.36) | NPC1RAB9ATRPC5MAPK1CLK1 | |
| SCHEMBL2908184 | 0.86 | RAB9A (0.45) | NPC1RAB9ATRPC5MAPK1CLK1 | |
| SCHEMBL2908188 | 0.86 | RAB9A (0.45) | NPC1RAB9ATRPC5MAPK1CLK1 | |
| SCHEMBL2904771 | 0.81 | NPC1 (0.38) | NPC1RAB9ATRPC5MAPK1CLK1 | |
| SCHEMBL2906684 | 0.81 | SMN1; SMN2 (0.39) | NPC1RAB9ATRPC5MAPK1CLK1 | |
| SCHEMBL2906701 | 0.81 | NPC1 (0.37) | NPC1RAB9ACLK1CLK2CLK4 | |
| SCHEMBL2906700 | 0.81 | NPC1 (0.37) | NPC1RAB9ACLK1CLK2CLK4 | |
| SCHEMBL2905168 | 0.81 | NPC1 (0.39) | NPC1RAB9ACLK1CLK2CLK4 | |
| SCHEMBL2905170 | 0.81 | NPC1 (0.39) | NPC1RAB9ACLK1CLK2CLK4 | |
| SCHEMBL2908348 | 0.77 | RAB9A (0.46) | NPC1RAB9ATRPC5MAPK1CLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825253-B2 | 2-aminoquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-11-02 | — | — | US | claimed |
| US-20080081907-A1 | 2-AMINOQUINOLINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-04-03 | — | — | US | claimed |
| US-7825253-B2 | 2-aminoquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-11-02 | — | — | US | disclosed |
| EP-2076495-B1 | QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES | HOFFMANN LA ROCHE (CH) | 2010-08-18 | — | — | EP | disclosed |
| EP-2076495-A1 | QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES | F.HOFFMANN-LA ROCHE AG (CH) | 2009-07-08 | — | — | EP | disclosed |
| WO-2008037626-A1 | QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-03 | — | — | WO | disclosed |
| US-20080081907-A1 | 2-AMINOQUINOLINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081907-A1 | 2-AMINOQUINOLINE DERIVATIVES | AR, ADRA2C, RCC2 | NPC1 1573/4885RAB9A 1336/4885TRPC5 1536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.